A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia

PHASE2UnknownINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 29, 2018

Primary Completion Date

May 1, 2020

Study Completion Date

May 28, 2020

Conditions
Idiopathic Hypersomnia
Interventions
DRUG

Pentetrazol (PTZ)

BTD-001 is an oral capsule of PTZ.

DRUG

Placebo oral capsule

Placebo will be presented as oral capsule.

Trial Locations (32)

10032

Columbia University - Department of Neurology, New York

10467

Albert Einstein College of Medicine, New York

15146

Consolidated Clinical Trials, Monroeville

17822

Geisinger, Danville

20815

The Center for Sleep and Wake Disorders, Chevy Chase

28078

Research Carolina of Huntersville, Huntersville

29201

Bogan Sleep Consultants, LLC, Columbia

30342

NeuroTrials Research Inc., Atlanta

31210

Sleep Practicioners, Macon

32789

Florida Premier Research Institute, Winter Park

33126

Sleep Medicine Specialists of South Florida, Miami

33511

PAB Clinical Research, Brandon

35213

Sleep Disorders Center of Alabama, Birmingham

40218

Kentucky Research Group, Louisville

46804

Fort Wayne Neurology, Fort Wayne

48314

Sleep and Attention Disorders Institute, Sterling Heights

55130

Neuroscience Center, Saint Paul

60062

Northshore Sleep Medicine, Northbrook

63017

St. Luke's Sleep Medicine and Research Center, Chesterfield

66214

Rowe Neurology Institute, Lenexa

73112

Lynn Health Science Institute, Oklahoma City

77063

Houston Sleep Center, Houston

78731

Future Search Trials, Austin

80301

REM Sleep Medicine, Boulder

85054

Mayo Clinic Hospital, Scottsdale

90404

Santa Monica Clinical Trials, Santa Monica

92128

Pacific Research Network, San Diego

92868

SDS Clinical Trials, Orange

94583

Sleep Medicine Specialists of California, San Ramon

95242

Intrepid Research, Cincinnati

98122

Swedish Medical Center, Seattle

02459

NeuroCare, Newton

Sponsors
All Listed Sponsors
lead

Balance Therapeutics

INDUSTRY